Provided by INmune Bio Primary and secondary resistance to therapy is a defining characteristic of progressive cancer in man. Patients and their clinical teams repeat the cycle of treatment, remission, relapse and retreatment until an effective therapy is found or the patient succumbs to the disease. Because of the devious biology of cancer, the “cure” […]
The post Targeting resistance to Immunotherapy with INB03 appeared first on PharmaVOICE.
Original Article: Targeting resistance to Immunotherapy with INB03